8 / 36
Enzalutamide at ADT progression reduced the risk of
radiographic progression versus bicalutamide
Bicalutamide
Enzalutamide
HR=0.51
(95% CI: 0.36–0.74)
p=0.0002
49%
RISK REDUCTION
100
0
33
30
27
21
24
18
15
12
9
6
3
0
50
Months
rPFS (%)
Enzalutamide, n
184
147
120
99
82
65
49
33
20
13
8
5
Bicalutamide, n
191
104
73
51
38
30
14
7
3
2
2
1
Shore ND, et al. Lancet Oncol 2016